Flagship Monograph · Metabolic Research
Retatrutide.
Triple-agonist GLP-1 / GIP / Glucagon peptide
Retatrutide is a novel investigational triple-agonist peptide targeting GLP-1, GIP and glucagon receptors simultaneously. In published early-phase clinical research it has demonstrated some of the most significant reductions in body weight and metabolic markers of any peptide studied to date, making it the leading subject of contemporary metabolic and obesity research.
€150,00
Specification
Batch profile.
- Purity
- ≥ 99.1%
- Molecular Wt.
- ~4731 g/mol
- Available in
- 30 mg vial
- Form
- Lyophilised
- Verification
- HPLC + MS
- Storage
- −20°C, dark
Research Context
A defining molecule in modern metabolic research.
Retatrutide is investigated in preclinical and early-phase research for its uniquely potent activity across three receptor systems. Published Phase-2 data has recorded some of the most substantial reductions in body composition, triglycerides and hepatic fat observed in any incretin-class molecule studied to date.
As a result it is one of the most studied molecules in contemporary obesity, hepatology and cardiometabolic research — and a foundational reference compound for laboratories working on next-generation multi-receptor agonists.
Pro-Peptides Supply provides Retatrutide to qualified research facilities in lyophilised form, verified by independent HPLC and mass-spectrometry analysis, with full certificate of analysis on request.
Certificate of Analysis
Independently verified purity.
Every batch of Retatrutide is analysed by an independent laboratory using UPLC/MS. The current batch tested at 99.627% and 99.691% purity. View the full test report and verify authenticity below.
- Verification Key (COA)
- 20265154
- Batch
- 2026515
- Reported Purity
- 99.627% / 99.691%
Legal & Compliance
For laboratory research use only.
Retatrutide supplied by Pro-Peptides Supply is an investigational research compound intended solely for in-vitro study by qualified researchers in appropriate laboratory settings. It is not a medicine, has not been approved by any regulatory authority for human use, and must not be administered to humans or animals. By purchasing you affirm your role as a researcher and your agreement to our compliance policy.